trial,pubID,pseudogroup,weeks,group,IgD-/IgM-/IgA-/IgG+/KO-/Antigen++ B cells
G002,G002-931,G002,16,3,6287.0
G002,G002-997,G002,16,3,3952.0
G002,G002-852,G002,16,1,3920.0
G002,G002-616,G002,16,1,3214.0
G002,G002-678,G002,16,1,2334.0
G002,G002-884,G002,16,3,3269.0
G002,G002-796,G002,16,3,2694.0
G002,G002-595,G002,16,3,1994.0
G002,G002-988,G002,16,3,1850.0
G002,G002-905,G002,16,1,1322.0
G002,G002-632,G002,16,3,1070.0
G002,G002-619,G002,16,1,1902.0
G002,G002-546,G002,16,1,1327.0
G002,G002-304,G002,16,3,781.0
G002,G002-477,G002,16,3,1092.0
G002,G002-371,G002,16,3,728.0
G002,G002-866,G002,16,3,1391.0
G002,G002-516,G002,16,1,912.0
G002,G002-758,G002,16,1,575.0
G002,G002-969,G002,16,1,933.0
G002,G002-302,G002,16,1,1122.0
G002,G002-427,G002,16,3,624.0
G002,G002-278,G002,16,3,512.0
G002,G002-462,G002,16,3,603.0
G002,G002-825,G002,16,3,240.0
G002,G002-810,G002,16,3,596.0
G002,G002-813,G002,16,1,334.0
G002,G002-834,G002,16,1,49.0
